litigation
confidence high
sentiment positive
materiality 0.85
Catalyst settles FIRDAPSE patent suit with Teva; generic entry barred until Feb 2035
CATALYST PHARMACEUTICALS, INC.
- Teva agrees not to market generic FIRDAPSE in the U.S. before February 25, 2035, if FDA approved.
- All ongoing FIRDAPSE patent litigation between Catalyst/SERB and Teva will be terminated.
- Litigation against remaining defendants Hetero (all patents) and Lupin (2037 patent) is ongoing.
- Confidential license agreement to be submitted to FTC and DOJ for review.